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Abstract
Background: A relatively high proportion of patients diagnosed with primary CNS lymphoma will experience
recurrent disease, yet therapy options are limited in salvage therapy. This is the first study to evaluate a
bendamustine-based combination regimen for the treatment of relapsed/refractory PCNSL and to characterize
bendamustine pharmacokinetics in the human CSF.
Methods: Patients received bendamustine 75 mg/m2 for two days as part of R-B(O)AD administered intravenously
every 4 weeks for up to 4 cycles. Response and adverse events of the regimen were assessed. A sparse sampling
strategy and population based modeling approach was utilized for evaluation of plasma and CSF levels of
bendamustine.
Results: Ten patients were enrolled into study of whom 70% were of refractory disease and with high IELSG
prognostic risk scores. The ORR of R-BOAD was 50% (95% CI, 0.24 to 0.76) with one patient achieving CR and four
PR. Primary toxicity of the regimen was reversible myelosuppression, mostly grade 3 or 4 neutropenia. The Cmax
mean for plasma and CSF were 2669 ng/mL and 0.397 ng/mL, respectively, and patients with response at deep
tumor sites displayed higher trends in peak exposure. Pharmacokinetic data was best described by a four-
compartment model with first-order elimination of drug from central plasma and CSF compartments.
Conclusions: R-BOAD is an effective salvage option for PCNSL, but with significant hematologic toxicity.
Bendamustine CSF levels are minimal; however correspond to plasma exposure and response.
Trial registration: ClinicalTrials.gov NCT03392714; retrospectively registered January 8, 2018.
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Background
Primary central nervous system lymphoma (PCNSL) is a
rare form of CNS malignancy representing 2–4% of all
primary CNS tumors and is of mainly diffuse large B-cell
lymphoma (DLBCL) origin [1, 2]. Despite high sensitivity
to radiation and chemotherapy, one third of the patient
population is refractory to first-line therapy and up to half
of the responders will relapse after remission from initial
treatment, mostly within the CNS [3, 4]. Salvage therapy
will be required for a significant percentage of the PCNSL
population, yet there is no current standard of therapy in
the relapsed/refractory (R/R) setting due to the lack of
data from randomized clinical trials. High dose metho-
trexate (HD-MTX) re-challenge in patients with previ-
ously MTX responsive disease is a feasible option
reporting high response rates, [5, 6] and numerous single
or combination therapy regimens have been examined in
small prospective studies with overall response rates ran-
ging from 30 to 55% [7–9].
Bendamustine is a bifunctional alkylating agent posses-
sing both alkylator and antimetabolite properties from a
mechlorethamine moiety and benzimidazole ring, respect-
ively. [10] Recently, several case reports have suggested
that bendamustine has modest clinical activity as single
agent therapy against relapsed PCNSL with reasonable
tolerability [11, 12]. However, the effect of this agent as
part of combination salvage therapy in patients with
PCNSL has not been established. The purine analog-like
properties of bendamustine are thought to augment the
apoptotic effects of pyrimidine analogs such as cytarabine,
and synergy against DLBCL cell lines has been shown to
be greatest when administered sequentially [13] where
therapeutic impact has been validated in several trials in-
volving mantle cell lymphoma patients [14, 15]. Similarly,
vincristine has documented efficacy against lymphoid ma-
lignancies when used in combination with bendamustine
in both in vitro and clinical studies [16, 17].
Although the role of rituximab in PCNSL has some con-
troversy, a recent meta-analysis has shown that additional
use of the CD20-targeted monoclonal antibody in initial
therapy correlates with higher response rates [18], and
other studies in the salvage setting have reported positive
outcomes, albeit a more modest response in prospectively
conducted trials [19, 20]. Based on the demonstrated activ-
ity and proposed additive mechanisms of these chemother-
apeutic agents, we investigated the bendamustine-based
combination regimen R-B(O)AD in patients with refractory
or relapsed primary CNS lymphoma. Evidence from previ-
ous preclinical tissue distribution studies and single agent
intravenous drug therapy trials in CNS malignancies sug-
gests that bendamustine penetrates brain and tumor tissue
[12, 21–23], and while cerebrospinal fluid (CSF) drug con-
centrations are commonly used as a surrogate marker of
CNS delivery, there are no clinical data available on the
pharmacokinetics (PK) of bendamustine in the CSF. In light
of rarity of the disease and difficulties in obtaining extensive
data samples, a nonlinear mixed-effects modeling approach
was considered appropriate for drug evaluation. Thus, we
evaluated the PK of plasma and CSF drug levels through a
population based model approach in a R/R PCNSL cohort
with the goals to define the currently unknown PK profile
of bendamustine in the CSF and to further characterize the
relationship between plasma and CSF drug levels, and the
influence of exposure on response to therapy.
Methods
Study eligibility
Eligible patients were ≥ 19 years of age with PCNSL of
DLBCL origin diagnosed by CNS lesion tissue biopsy, and
in relapse or refractory to frontline chemotherapy or radi-
ation, with confirmed evidence of disease progression by
contrast enhanced magnetic resonance imaging (MRI).
Additional requirements were Eastern Cooperative Oncol-
ogy Group (ECOG) performance status 0–2 and adequate
hematologic and organ function including absolute neu-
trophil count (ANC) ≥ 1000/uL, platelets ≥100,000/uL,
total bilirubin ≤1.5 x upper limit of normal (ULN), trans-
aminases ≤3 x ULN, and serum creatinine ≤2.0 x ULN.
Patients with uncontrolled infection, therapy with myelo-
suppressive chemotherapy or biologic therapy < 21 days
prior to registration, persistent toxicities ≥ grade 3 from
prior chemotherapy, history of thromboembolic episodes
≤3 months prior to registration, active hepatitis B or C
with uncontrolled disease, or with active other malignancy
requiring treatment that would interfere with assessments
of lymphoma response to protocol treatment were ex-
cluded from enrollment.
Study design and treatment
This was a prospective, open-label, pilot study investigating
the safety and efficacy of the bendamustine-based combin-
ation regimen R-B(O)AD, designed to define CSF and
plasma PK profiles of bendamustine in R/R patients. All pa-
tients received either R-BOAD or R-BAD intravenously (ri-
tuximab 375 mg/m2 on day 1; vincristine 1.4 mg/m2 on day
1, omitted in patients ≥70 years of age due to risk of neuro-
toxicity; bendamustine 75 mg/m2 over 1 h on days 2 and 3;
cytarabine 1000 mg/m2 over 3 h on days 2–4; dexametha-
sone 20 mg on days 1–4), every 4 weeks up to 4 cycles. Ini-
tial reduction of bendamustine or cytarabine dosage was
allowed if deemed necessary by the physician due to elderly
age or poor performance status. Subcutaneous granulocyte
colony-stimulating factor support was administered post
chemotherapy on starting day 7 of the cycle in all patients
until ANC ≥ 500/uL. Treatment cycles were delayed until
hematologic parameters allowed for the next cycle of
therapy (i.e. ANC ≥1000/uL, platelets ≥75,000/uL). If a
cycle was postponed > 1 week due to hematologic toxicity
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bendamustine and cytarabine doses were reduced by was
25% in subsequent cycles. For vincristine, drug dose was re-
duced by 50% in the case of moderate neurotoxicity (grade
2), and if severe (grade 3 or 4) was discontinued for all sub-
sequent cycles.
Efficacy and safety measurements
Baseline assessments included physical and neurological
examination, laboratory studies, ocular slit lamp and CSF
examination, and contrast enhanced cranial MRI. Once en-
rolled into study, response was assessed after every two cy-
cles of therapy or at any time point where progression was
suspected. Evaluation of response to treatment was based
on criteria defined by Abrey et al. [24]. Patients who did not
respond to the first two cycles of therapy were discontinued
from study. The efficacy of the combination regimen was
determined by ORR, defined as patients with complete (CR)
or partial response (PR). Two-sided 95% confidence inter-
vals (CIs) are given for efficacy endpoint ORR, using the
Wilson method for small sample size [25]. After completion
of study treatment, patients with PR or CR were reassessed
every three months. Safety was assessed after each treatment
cycle by documentation of adverse events based on the NCI
Common Terminology Criteria (version 4.0) through phys-
ical examination and clinical laboratory results.
Pharmacokinetic assessments
Utilizing sparse sampling strategies, plasma and CSF
samples for PK analyses were acquired in pairs on the
first day of bendamustine administration (day 2 of com-
bination regimen), one pair per cycle per patient, with a
cumulative target collection of three observations per
time point. Sampling time points (0 min, 30 min, 1 h,
3 h, and 8 h post completion of bendamustine infusion)
were selected based on previously published plasma
pharmacokinetic studies showing near complete elimin-
ation of drug within 8 h of infusion completion [26, 27].
Additional time points were investigated if deemed ne-
cessary to clarify plasma and CSF exposure profiles of
bendamustine, but each patient was not to exceed three
sampling time points during the entire course of ther-
apy. At designated time points 5 mL of whole blood and
2 mL of CSF by lumbar puncture were drawn into evac-
uated EDTA and clear tubes, respectively, and immedi-
ately placed on ice. Within 1 h, blood samples were
centrifuged at 1500 rpm for 10 min at 4 °C, supernatant
withdrawn and transferred into 100 uL aliquots. Ali-
quots of plasma and CSF samples were stored at − 70 °C
until quantification. Bendamustine drug concentrations
were determined by validated liquid chromatography/
tandem mass spectrometry (LC-MS/MS) methodology
with modifications, and a lower limit of quantification
(LLOQ) of 0.05 ng/mL for CSF and 5 ng/mL for plasma
[28]. The inter-day coefficients of variation for the assay
of bendamustine concentrations were ≤ 3.0% and ≤ 9.4%
for plasma and CSF, respectively.
CSF exposure estimates and PK model
CSF exposure was estimated as Cmax,CSF/Cmax,plasma and
AUCCSF/AUCplasma ratios. Non-compartmental methods
were used to calculate the area under the concentration–
time curve (AUC0-inf ) in WinNonlin, version 5.2 (Phar-
sight, St. Louis, MO, USA). The relationship between drug
levels and tumor location, and interim responder status
(i.e. response after two cycles of treatment or first sus-
pected progression) was assessed by classifying patients
according to observed maximum plasma and CSF concen-
trations, and the involvement of deep structures.
Population PK analyses were performed with NONMEM
software, version 7.3 (ICON Development Solutions, Ellicott
City, MD, USA) using the first-order conditional estimation
method (FOCE) and ADVAN6 routine. Processing of NON-
MEM output and generation of plots were conducted using
Xpose 4.5.3 and Sigma plot 12.0 (SYSTAT, Salano, Califor-
nia, USA). Plasma concentration of bendamustine was best
described by a two-compartment model, parameterized for
central (V1) and peripheral (V2) compartment volumes of
distribution with inter-compartmental (Q1) and elimination
clearance (CL). For addition of the CSF compartment, a bio-
phase reservoir was applied between the central plasma and
CSF compartment. The structural model for CSF concentra-
tion data was parameterized for biophase (V3) and CSF (V4)
compartment volumes of distribution with CSF elimination
clearance (CLcsf) and inter-compartmental clearances Q2
and Q3. Inter-individual variability (IIV) was modeled with
an exponential error model and residual variability (RV) was
assessed using a proportional error model.
The most appropriate pharmacostatistical model was se-
lected on the basis of goodness-of-fit plots, precision of es-
timates, and the likelihood ratio test using NONMEM
generated objective function values (OFV). Goodness-of-fit
plots included observed and predicted individual profiles,
population predicted estimates, and conditional weighted
residuals [29]. Precision of the population estimates was
evaluated on the basis of relative standard errors (RSE, %)
and inter-individual variability was estimated in terms of
the coefficient of variance (CV, %). The accuracy and ro-
bustness of the final population model was evaluated using
a non-parametric bootstrap analysis. Replication sets of the
original data were generated (N = 1000) to which the final
population model was re-fit and stability of the model was
evaluated by comparing final model parameter estimates to
the median and 90% CIs of the bootstrap replicates.
Results
Patient characteristics and treatment
Between January 2016 and March 2017, ten patients
were enrolled into study at a single center in South
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Korea. All subjects had CNS lymphoma of DLBC origin
and a majority of the patients were with poor prognostic
scores based on the International Extranodal Lymphoma
Study Group (IELSG) risk scoring system [30]. All pa-
tients had previously received high dose methotrexate as
part of initial treatment and most patients were of re-
fractory disease. Of the three relapsed patients, one pa-
tient entered study at second relapse. Twenty-seven
cycles of R-B(O)AD were administered, at a median of
three cycles per patient, and vincristine was omitted in
four patients. Four patients were treated with initial
dosage reductions in bendamustine and cytarabine by
25%, due to elderly age (> 70 years; one patient 78 years
of age received cytarabine 500 mg/m2). Chemotherapy
was delayed in five of the 27 cycles but further dose
reduction was not required as no subsequent cycle was
postponed longer than 7 days. G-CFS was given to all
patients. Patient characteristics and responses are sum-
marized in Table 1.
Efficacy and safety
The ORR of R-B(O)AD was 50% (95% CI, 0.24 to 0.76),
one patient achieving CR (10%) and four PR (40%). The CR
patient showed lymphomatous infiltration in the left optic
nerve with thickening visible on MRI that completely re-
solved after the second cycle of R-BAD. All subjects who
progressed on salvage therapy were patients of refractory
disease. One of these patients showed near complete reso-
lution of multiple tumor sites during interim analysis
(Fig. 1), however developed new lesions after the third cycle
of therapy. Four of the five patients who progressed during
study treatment received WBRT post salvage therapy. Pri-
mary toxicity of the combination regimen was reversible
myelosuppression, mostly grade 3 or 4 neutropenia (89% of
cycles). Grade 3 febrile neutropenia was observed in 33%,
grade 3 or 4 thrombocytopenia in 85%, and grade 1 or 2
anemia in 70% of treatment cycles. The most common
non-hematological toxicities were nausea and diarrhea, 30
and 19%, respectively, mostly grade 1 or 2. Infection
(mostly pneumonia) was observed in three patients, all
requiring antibiotic therapy, and one resulted in treatment
related mortality. This was a 73 year old patient who
received four cycles of R-BAD therapy with documented
partial reduction in tumor after cycle two, and during
cycle four developed urinary catheter related Klebsiella
pneumoniae infection and progressive bronchopneumonia
on chest imaging, with delayed hematologic recovery.
Pharmacokinetic exposure data
A total of 28 plasma and 16 CSF samples were collected.
Time of maximum concentration (tmax) was found at the
end of infusion (tmax,plasma = 1 h) for plasma and at 0.5 h
after end of infusion (tmax,csf = 1.5 h) for CSF. The Cmax
mean for plasma was 2669 ng/mL (SD ±1176 ng/mL)






























3 M/75 1 4 Rel HDMTX +
WBRT;
MPV-A
ND; L optic nerve 4 CR 21.7/> 21.7
4 M/42 2 3 Ref HDMTX D; basal ganglia 2 PD 1.6/9.1
5 M/78 2 3 Rel HDMTX+
AraC
ND; L parietal 4 PR 6.9/> 6.9
6 F/55 2 4 Ref HDMTX+
AraC
ND; L frontal, R temporal 3 PD 2.8/3.3
7 F/47 1 2 Ref HDMTX+
AraC
Dt; L frontal, periventricular 1 PR 2.8/2.8
8 F/73 2 5 Rel HDMTX+
AraC
ND; L frontal 4 PR 4.4/4.4
9 M/75 2 4 Ref HDMTX+
AraC
NDt; L frontal 2 SD 4.2/> 4.2
10 M/65 2 5 Ref HDMTX Dt; L frontal, basal ganglia 2 PR 3.9/3.9
Abbreviations: M, male; F, female; PS, performance status; Rel, relapsed; Ref, refractory; HDMTX, high dose methotrexate; AraC, cytarabine; WBRT, whole brain
radiotherapy; MPV-A, methotrexate, vincristine, procarbazine, cytarabine; D, deep; ND, non-deep; L, left; R, right; CR, complete response; PR, partial response; SD,
stable disease; PD, progressive disease; PFS, progression free survival; OS, overall survival
*IELSG risk = intermediate (IELSG score 2–3), high (IELSG score 4–5)
tPatients with leptomeningeal involvement in recurrent disease
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and for CSF 0.397 ng/mL (SD ±0.160 ng/mL). CSF/
plasma exposure ratios were calculated to be 0.015 and
0.025% for Cmax and AUC0-inf, respectively. Individual
observations at Cmax,plasma and Cmax,csf were available for
eight patients. All patients who showed an interim re-
sponse were subjects with involvement of non-deep
structures as classified by Ferreri et al. [30] and those
displaying tumor regression at deep sites possessed
higher trends in Cmax,plasma and Cmax,csf values (Fig. 2).
Population pharmacokinetic model
Pharmacokinetic data was best fit by a four-compartment
model incorporating two plasma compartments (central
and peripheral) with drug distributing from central plasma
into an intermediate biophase reservoir and then into a final
CSF compartment, with first-order elimination of drug from
both central plasma and CSF compartments (Fig. 3). The
biophase compartment was required to account for the
delay in time to reach maximum drug concentrations in the
CSF after infusion completion, compared to the immediate
peak in plasma achieved at the end of IV infusion. The
overall volume of distribution in plasma (Vplasma =V1 +V2
= 19.7 L) was similar to previously reported values (~ 20 L)
as was elimination clearance from the central plasma
compartment (32.5 L/hr. for patient with BSA= 1.675) [26,
27]. Inter-individual variability in pharmacokinetic variables
was moderate, with coefficient of variance values near 40%.
A proportional model was employed to assess residual vari-
ability for which CV% was 17%. Overall, observed benda-
mustine concentrations in plasma and CSF were adequately
fit by population predicted median values, indicating ability
of the final model to describe central tendencies (Fig. 4). Es-
timates for the final model were similar to bootstrap repli-
cates and were contained within the 90% CI, representing
absence of significant bias. The PK parameter mean esti-
mates with associated standard errors and the 90% boot-
strap confidence intervals are presented in Table 2.
Discussion
This was a prospective pilot trial investigating a
bendamustine-based combination regimen in patients
with R/R primary CNS lymphoma. Recurrent disease is
difficult to treat in that progression is usually rapid and
aggressive leading to significant impairment in perform-
ance status and neurological deterioration, a limited
number of salvage strategies exist, and survival outcomes
are suboptimal despite additional therapy. The 50% ORR
of the study regimen falls within the range of efficacy
a
b
Fig. 1 Resolution of multi-focal (left frontal and right temporal lobe) disease in a 65 year old patient (ID No. 6) a) before and b) after two cycles
of R-BOAD at interim analysis
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prospectively observed with current salvage regimens
utilized in R/R PCNSL. A previous case series report
demonstrated a best response rate of 50% to single agent
bendamustine therapy with acceptable toxicity but was
retrospective in nature and showed a relatively short
lived response. In this study, utilization of mechanistic-
ally augmenting chemotherapeutic agents resulted in an
active salvage regimen with remarkable effects observed
on imaging in patients showing response. Such activity
may largely be attributed to the anticipated synergy
effect of combination bendamustine and cytarabine,
considering the majority of the patients had progressed
despite previous treatment with cytarabine as a part of
induction therapy.
However, such synergistic effects of the combination also
lead to significant marrow suppression, and hematologic
toxicity observed with R-B(O)AD was considerable with
grade 3 or 4 neutropenia and thrombocytopenia experi-
enced in > 85% of treatment cycles. The rate of toxicity
observed was somewhat higher than that reported in a
previous study investigating treatment of mantle-cell
non-Hodgkin lymphoma patients with bendamustine
(70 mg/m2) and cytarabine (800 mg/m2) combination
therapy [14], and may be explained by ethnic and disease
differences in the study population. Severe infection was
observed in three patients, all with involvement of the
lungs, one patient with underlying COPD disease and
another with a history of fungal pneumonia. Due to
Fig. 2 Relationship between interim response status and a) plasma Cmax and b) CSF Cmax bendamustine concentrations, and tumor location.
Deep structures include periventricular regions, basal ganglia, brainstem, and cerebellum regions. Closed circles (•) represent responders and
open circles (°) non-responders. Patient identification numbers are notated and the dashed line depicts mean Cmax values for plasma and CSF.
Bendamustine exposure was not significantly higher for the patient resulting in treatement related death (ID No. 8)
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significant myelosuppression despite the use of prophylactic
growth factor support, study protocol was later amended
with reduction in cytarabine dosage to 500 mg/m2 and
stricter criteria for dose adjustments in the case of severe
cytopenias.
To our knowledge, this is the first study to characterize
the pharmacokinetics of bendamustine in human CSF.
Given multiple sampling of the CSF through lumbar
puncture is not feasible for both medical and ethical rea-
sons, a sparse sampling method and population PK
approach was employed with collection of CSF at different
time points among patients. CSF concentrations of benda-
mustine were minimal compared to plasma values with an
AUC exposure ratio of 0.025%. Although absolute values
of CSF drug levels were much lower than those in plasma,
higher trends in maximum peak concentrations of drug in
Fig. 3 Schematics of structural model used for bendamustine. Abbreviations: V, volume of distribution; Q, inter-compartmental clearance; CL,
clearance of central plasma compartment; CLcsf, clearance of CSF compartment
Fig. 4 Bendamustine concentration-time profiles. Circles represent observed values for plasma (•) and CSF (°) drug levels. Best-fit curves from the
final population PK model are shown for plasma () and CSF (−—)
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the CSF showed correlation to tumor response, particu-
larly in patients with lymphoma involvement of deep brain
structures. Among patients with observations sampled at
tmax,plasma and tmax,csf, all subjects with tumors outside
deep regions showed significant tumor regression regard-
less of PK concentrations. This is in line with the IELSG
scoring system in which disease involvement of deep
structures is an independent prognostic variable associ-
ated with poor survival [30].
The inclusion of a biophase reservoir between the cen-
tral plasma and CSF compartment allowed for the ob-
served delay in time to peak concentrations of the CSF,
and may be representative of anatomical structures that
are part of the CSF macrocirculation but are farther
from the sampled lumbar puncture site. The concentra-
tion time profile of the biophase reservoir was simulated
using the population PK model and drug exposure was
predicted to be similar to that of the CSF compartment
(Additional file 1: Figure S1). Clearance of bendamustine
from the CSF compartment was rapid with an elimin-
ation half-life t1/2, csf = 0.30 h calculated from model
parameter estimates. Bendamustine like other nitrogen
mustards has limited stability and undergoes degradation
by hydrolysis, which increases in the presence of water
and higher temperatures [31, 32]. Such chemical proper-
ties of bendamustine may contribute to the extensive
elimination of drug observed in the CSF.
A previous tissue distribution study of IV 14C-bend-
amustine demonstrated radioactivity in brain tissue of
mice, rats, and dogs, suggesting permeability of drug
through the blood brain barrier (BBB) [33]. Despite
the association observed between bendamustine con-
centrations in the CSF and drug activity, it is doubtful
that such low concentrations found in our study are
representative of true drug levels in the brain paren-
chyma. This may partially be explained by differences
in drug penetration through the BBB and the
blood-CSF barrier due to variations in the endothe-
lium and transporter expression, in which case CSF
concentrations would not serve as an adequate
marker of drug delivery to the tumor location. Such
discrepancies between drug levels in the CSF and
brain tissue have been reported for several chemo-
therapeutic agents. Temsirolimus, an mTOR inhibitor,
has demonstrated drug levels in tissue above those in
the plasma of glioma patients, yet in another study
negligible CSF drug levels were observed in CNS
lymphoma patients [34, 35]. Single agent rituximab
therapy has shown clinical activity in disease of the
CNS but also possesses poor detectable drug levels in
the CSF after IV administration [20]. Therapeutic
levels of such drugs in the brain parenchyma are
thought to be achieved by penetration of a BBB that
is with compromised integrity due to the highly disor-
dered and permeable vasculature of the infiltrating
tumor [36]. In these settings drug concentrations are
expected to decrease with increasing distance from
the tumor bulk.
Conclusion
A relatively high proportion of patients with PCNSL will
experience progression of disease, yet the number of
prospective trials on salvage therapy remains small due
to the rarity of disease and rapidly progressive nature. It
is accepted that salvage therapy is beneficial and signifi-
cantly improves survival in comparison to palliative care.
Although this study reports data from a limited number
of patients, it supports the use of a bendamustine-based
combination regimen as an option for salvage therapy,
especially in patients who are no longer chemo-sensitive
to methotrexate or those who have developed cumula-
tive renal or neurotoxicity from treatment. Hematologic
toxicity of the regimen is significant but manageable
with dose reduction and supportive care. A lower dosage
of cytarabine at 500 mg/m2 may be more feasible to
avoid prolongation of significant marrow suppression
and will be investigated in a Phase II study. Evaluation
of plasma and CSF data with development of a popula-
tion PK model shows CSF drug levels are low with rapid
decline and are unlikely to be an accurate predictor of
drug concentrations at the tumor site, thus should not
be utilized as a surrogate of CNS drug delivery. However,
trends in higher peak bendamustine concentrations in
Table 2 Population PK model parameter estimates and







V1 14.9 19.2 14.1 4.9 20.7
CL 32.5 10.5 31.4 23.9 39.2
V2 0.508 14.4 0.455 0.186 0.846
Q1 0.238 15.3 0.205 0.041 0.660
V3 0.323 9.8 0.322 0.186 0.442
Q2 0.569 15.8 0.569 0.344 0.836
V4 0.032 40.9 0.032 0.014 0.041
Q3 0.793 16.8 0.795 0.573 1.360
CLcsf 0.075 43.5 0.075 0.059 0.140
IIV V1 0.230 42.9 0.220 0.011 0.480
IIV CL 0.089 39.9 0.086 0.014 0.190
RV 0.420 17.4 0.390 0.210 0.620
Abbreviations: RSE (%, for structural parameter estimates), relative standard error;
CV (%, for IIV), coefficient of variance; CI, confidence interval; V (L), volume of
distribution; CL (L/h), elimination clearance; Q (L/h), inter-compartmental
clearance; CLcsf (L/h), CSF compartment clearance; IIV, inter-individual variability;
RV, residual variability
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both plasma and CSF were observed for patients who
showed response to treatment in deep tumor locations.
Additional file
Additional file 1: Figure S1. Simulations of bendamustine concentration-
time profiles for compartments included in final PK model. C1, central plasma
compartment; C2, peripheral plasma compartment; C3, biophase
compartment; C4, CSF compartment. (DOCX 53 kb)
Abbreviations
AraC: Cytarabine; CI: Confidence interval; CL: Clearance of central plasma
compartment; CLcsf: Clearance of CSF compartment; CR: Complete response;
CSF: Cerebrospinal fluid; CV: Coefficient of variance; D: Deep; DLBCL: Diffuse
large B-cell lymphoma; F: Female; HDMTX: High dose methotrexate;
IELSG: International Extranodal Lymphoma Study Group; IIV: Inter-individual
variability; L: Left; M: Male; MPV-A: Methotrexate, vincristine, procarbazine,
cytarabine; ND: Non-deep; ORR: Overall response rate; OS: Overall survival;
PCNSL: Primary central nervous system lymphoma; PD: Progressive disease;
PFS: Progression free survival; PK: Pharmacokinetics; PR: Partial response;
PS: Performance status; Q: Inter-compartmental clearance; R: Right; R/
R: Relapsed/refractory; Ref: Refractory; Rel: Relapsed; RSE: Relative standard
error; RV: Residual variability; SD: Stable disease; V: Volume of distribution;
WBRT: Whole brain radiotherapy
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